Navigation Links
Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
Date:12/7/2011

AUSTIN, Texas, Dec. 7, 2011 /PRNewswire/ -- Medicare carrier Palmetto GBA is proposing new processes that govern how it will handle code stack claims for molecular diagnostic tests (MDT) and laboratory-developed tests (LDT) in the J1 region, to become effective on February 27, 2012. This marks the first known effort by a payer to address specific problems caused when laboratories submit code stacked claims for genetic tests and molecular diagnostics assays.

These important developments will be covered in a special audio conference to be conducted on Tuesday, December 20, 2012, by The Dark Report & Darkdaily.com. Featured speakers from Palmetto GBA are: Elaine Jeter, M.D., Medical Director; and Mike Barlow, Vice President. Jeter and Barlow will discuss five important subjects:

  •  Why the use of code stacks in claims for genetic and molecular tests creates issues for payers.
  •  How the two proposed local coverage determinations (LCD) will address the most important issues triggered by code stacking.
  •  Introduce labs to the Molecular Diagnostic Services Program (MolDx) and how a molecular test registry will be used in the MolDx program.
  • Describe the steps involved in using the MolDx registry, which includes each lab to register each of its MDTs and LDTs to obtain a Z-Code for each assay, and how labs should next submit the clinical and scientific material in support of each assay that will be used to make a coverage determination of that test.
  • What will take place in order for the coverage determination to be made for each assay with a Z-Code.
  • How code stacked claims for genetic and molecular tests from the J1 region will be handled prior to February 27, 2012, and after that date. 

This audio conference is an open public forum which allows every laboratory professional to hear these presentations and participate in the question and answer session that follows. It is also an opportunity for lab consultants and experts in genetic and molecular testing to hear, first-hand, the details behind the two proposed LCDs and MolDx, the proposed Molecular Diagnostic Services Program.

This high-value, low-cost 90-minute audio conference is of critical interest to laboratories performing molecular diagnostic tests and lab-developed tests. As noted above, Palmetto GBA executives will directly address the issues of concern to laboratory leaders to be caused by the growing number of code-stacked claims. In addition, the executives will answer specific questions from the audience during a phone Q&A. Media representatives who would like to listen to this audio conference should email Justin M. Clark at: 512-264-7103.

THE DARK REPORT (www.darkreport.com) invites you to participate in this important and timely new audio conference. For more information or to register, call toll-free: 800-560-6363

For additional information, Contact: Justin M. Clark, 512-264-7103


'/>"/>
SOURCE THE DARK REPORT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. What Hospitals Must Do to Thrive -- Not Just Survive -- on Medicare Margins
2. Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy
3. Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar
4. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
5. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
6. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
7. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
8. Finance Committee Begins Markup - Lab Fee Converted to Medicare Cut
9. Noridian Medicare Now Covers Renessa(R) Treatment for Incontinence in Women
10. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
11. The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):